Obermatt
See Similar Stocks →

Flags

Financial distress

Idorsia

SWX:IDIA · CH0363463438
BiotechnologySmall

360

14
Profit price34
Owner Earnings Yield1
Dividend Yield97
Price/Sales48
EV / Gross Profit19
Price/Book72
Return on Capital4
Cash Return on Capital4
EBIT Margin30
Gross Profitability67
Accruals80
Owner Earnings Margin54
Sales growth34
Profit growth44
Reinvestment25
Price momentum89
Debt load3
Refinancing50
Debt Payback1
Liquidity51
Analyst ratings34
Opinion Changes50
Price Target Upside4
Market mood15
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Idorsia doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySwitzerland
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeSWX
Founded2017
Websiteidorsia.com
ISINCH0363463438
Last UpdateApr 2, 2026
Indices
SPI (Switzerland)
Themes
NeurologyPsychiatryCardiovascularInfectious DiseasesCentral Nervous SystemOncologyChronic DiseasesImmunologyBiotechnologyHealth CareScience and Engineering

Description

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs. Business Segments The company operates through business segments: pharmaceuticals, consumer health products, bi…

Analysis

Middle-of-the-road

Idorsia Ltd is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 6/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
30
2026

All-time high

30

Jun 2026

All-time low

18

Mar 2026

Average rank

24

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
48
—
—
—
Price/Earnings
95
—
—
—
Price/Book
72
—
—
—
Dividend Yield
97
—
—
—
Value (overall)
100
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Idorsia with its peers
MindMaze Therapeutics Holding
SWX:MMTX
49
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ABIVAX
PAR:ABVX
26
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kuros Biosciences
SWX:KURN
80
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tiziana Life Sciences
NAQ:TLSA
67
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Roivant Sciences
NSQ:ROIV
47
CountryUK
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Genmab
CPH:GMAB
40
CountryDenmark
IndustryBiotechnology
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →